KTN's online platform helps you to make the connections you need

 

The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.

 

The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

« go back

Piramal invests in Scotland site offering

Piramal Enterprises' Pharma Solutions division announced that it is looking to strengthen its position in contract commercialization of antibody-drug conjugates (ADCs) over the next five years. The CDMO has introduced a new “Proof of Concept” service, designed to bring the most promising targets into clinical development more quickly.

Piramal, now in its fifth year of production on the first-ever ADC (Adcetris) to be commercialized, has set a target of becoming a market leader in the development and manufacturing of ADCs over the next five years. This drive is based on Piramal’s focused investments at its current site in Grangemouth, United Kingdom and its recent acquisition of Coldstream, a specialized ADC fill/finish site, in Kentucky, US.

Piramal believes that the ADC market will accelerate during the next few years because of a steady increase in the number of potential drug targets entering into the clinical phase. The CDMO expects approximately eight drugs to move into commercial production by 2020 and suggests that despite the increase in development targets for ADCs, the global contract manufacturing sector still remains significantly under resourced with only a handful of players with experience and even less with the required regulatory accreditations. Piramal has been gradually expanding its internal teams and has nearly 150 ADC specialists across its global sites.

Vivek Sharma, CEO, Pharma Solutions, Piramal Enterprises, commented in a press statement, “The situation with ADCs mirrors what happened when monoclonal antibodies (mAbs) first started to commercialize. At present, very few CMOs have the facilities or, just as crucially, the experience to develop them. At the moment, there are only two CMOs, including ourselves, which are leading the charge in the commercial manufacturing of ADCs. Piramal is targeting winning at least one in every two commercial contracts coming to market over the next few years”.  

Piramal views the acquisition of Coldstream’s fill finish site earlier this year as the final piece in the jigsaw puzzle and is now bullish about its prospects in the market.

Research on ADCs shows that there will be at least 50 targets entering the clinical testing pipeline by 2020. Over the next few years, it is likely that there will be a wave of consolidations within the CDMO sector to acquire ADC technologies.